Sheffield International is marketing and actively pursuing strategic opportunities both for GBP Capital and entities within it's portfolio of companies.

GBP Capital provides venture funding and assistance to early and mid-stage life science companies. They target companies with novel approaches to diagnostics, therapeutics, and medical devices, that will change the face of healthcare innovation in the future. GBP shares the drive and vision of it's portfolio companies to collaborate with them in accelerating growth and building successful business ventures. GBP Capital's existing portfolio is diversified, with investments in therapeutics, medical devices, medical products, and intellectual property, yet there exists a strong synergy amongst the portfolio companies.

GBP Capital is focused on investing in companies with technologies that leverage and build upon these breakthroughs, as well as other major developments taking place within the life-sciences industry. GBP Capital has assembled a core team, whose backgrounds include venture capital, corporate management, investment banking and biotech. We have supplemented our planning and due diligence with a world-class scientific advisory board, comprising of a world renown cancer researcher, one of the world's foremost gene therapy researchers and chair-elect of the academic counsel of the Salk Institute, and the first scientist and entrepreneur to develop and use lentiviral vectors in human trials.

Read more: GBP CAPITAL



Working with Lighting Science Group via a strategic relationship with Lumetech Group our advisors and colleagues are serving as interlocutors for multinational entities that seek to reduce their energy consumption to a fraction of the original cost with the implementation of revolutionary lighting systems. Lighting Science is the world’s leading maker of advanced lighting products.  By applying the science of light, they outperform the competition and delivers on the promise of LED technology for indoor and outdoor lighting projects from large to small in project size.  From outer space to major cities and now your home, Lighting Science products and solutions are environmentally friendly, save money and increase energy independence.

Read more: Lighting Science Group



Lentigen is pioneering an inevitable path to the future of medicine.

Founded in 2004, Lentigen is dedicated to advancing biomedicine and improving human health by the development and provision of Biotherapeutics, Vaccines & Research Products. The company intends to become a leader in the development of such Biologic Products using its proprietary Lentiviral Vector (LV) technology, widely recognized by the scientific community as the most efficient method for stable gene delivery into cells. Under the direction of an experienced management team, Lentigen has established a strong intellectual property position in the area of LV technology. The combination of strong academic and corporate collaborations that support a robust proprietary pipeline will fuel company growth, while a diversity of funding models and business opportunities will mitigate risk.

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading company for the development of Lentiviral vector technology.

Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The International AIDS Vaccine Initiative, The Bill and Melinda Gates Foundation, The National Institutes of Health, PATH, Expression Therapeutics, Epixis SA, The University of Pennsylvania, The University of Pittsburgh and The U.S. Army.  The Company has succeeded in funding much of it's work through government grants accelerating it's development and milestones of achievement.


Read more: Lentigen